NNOX - FDA clears Nanox's HealthOST device which can be used for spine analysis in osteoporosis

Nano-X Imaging (NASDAQ:NNOX) on Thursday said its unit Nanox.AI got a U.S. Food and Drug Administration (FDA) premarket medical device clearance for its HealthOST device, an AI software that provides clinicians with a spinal analysis to help in the treatment of musculoskeletal disease, such as osteoporosis. The device can also measure and analyze vertebral fractures and low bone density. NNOX said this is Nanox.AI's 10th FDA clearance. HealthOST is indicated for use in patients aged 50 and over undergoing CT scan for any clinical indication that includes at least four vertebrae in the T1-L4 portion of the spine and T11-L4 portions of the spine. NNOX stock -1.8% to $9.53 in morning trade.

For further details see:

FDA clears Nanox's HealthOST device which can be used for spine analysis in osteoporosis